Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.~* Have moderate to severe AD, including all of the following:~  * EASI score ≥16~ * IGA score of ≥3~ * ≥10% of BSA involvement~* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.~* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).~* Agree to use emollients daily.~Exclusion Criteria:~* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.~* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.~* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.~* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).~* Have been treated with the following therapies:~  * monoclonal antibody for less than 5 half-lives before randomization~ * received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization~ * received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study~ * have had an intra-articular corticosteroid injection within 6 weeks of planned randomization~ * probenecid at the time of randomization that cannot be discontinued for the duration of the study~* Have high blood pressure characterized by a repeated systolic blood pressure \>160 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 mm Hg.~* Have had major surgery within the past eight weeks or are planning major surgery during the study.~* Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.~* Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.~* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.~* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.~* Have specific laboratory abnormalities.~* Have received certain treatments that are contraindicated.~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 milligram (mg) Baricitinib (Type: EXPERIMENTAL): 2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
- 1 mg Baricitinib (Type: EXPERIMENTAL): 1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally every day.

Based on this trial design, predict the completion outcome and termination type (if applicable).